Exhibit 99.1

 

LOGO   Contacts:    Vincent J. Milano
     Vice President, COO, CFO and Treasurer
     VIROPHARMA INCORPORATED
     Phone (610) 321-6225
      

Will Roberts

     Director, Corporate Communications
     VIROPHARMA INCORPORATED
     Phone (610) 321-6288

VIROPHARMA INCORPORATED

Reports 2005 Financial Results and Provides Guidance

Exton, PA, February 28, 2006

VIROPHARMA INCORPORATED (Nasdaq: VPHM) reported today its financial results for the fourth quarter and twelve months ended December 31, 2005.

Net sales of Vancocin® were a record $40.3 million for the fourth quarter of 2005 and $125.9 million for the twelve months of 2005. This compares to $8.3 million for the fourth quarter of 2004. Sales during the 2004 periods are not comparable to the 2005 periods as the Company acquired Vancocin from Eli Lilly and Company in November 2004. Unaudited net sales of Vancocin for twelve months of 2004 were $54.0 million.

Operating income in the fourth quarter and twelve months ended December 31, 2005 was $28.2 million and $88.1 million, respectively, compared to operating income in the fourth quarter of 2004 of $9.8 million and operating loss in the twelve months of 2004 of $12.0 million. The improvements in operating results from 2004 to 2005 were driven primarily by sales of Vancocin and the related cost of sales.

The Company recorded an income tax benefit of $47.8 million in the fourth quarter of December 31, 2005 to establish deferred tax assets. In addition, for the twelve months of 2005, the Company recorded $10.0 million in income tax expense. These two items resulted in a net income tax benefit for the year of $37.8 million.

Net income in the fourth quarter and year ended December 31, 2005 was $72.7 million and $113.7 million, respectively, compared to net income of $5.8 million and net loss of $19.5 million for the same periods in 2004. Net income per share for the quarter ended December 31, 2005 was $1.21 per share, basic, and $1.17 per share, diluted, compared to a net income of $0.22 per share, basic and diluted, for the same period in 2004. Net income per share for the year ended December 31, 2005 was $2.56 per share, basic, and $2.02 per share, diluted, compared to a net loss of $0.73 per share, basic and diluted, for the same period in 2004.

The primary drivers of the improved results were the effects of operating income and the income tax benefit of establishing deferred tax assets in 2005, partially offset by debt-related costs. The $47.8 million of income tax benefit that was recorded to establish net deferred tax assets increased net income for the fourth quarter of 2005 by $0.80 per share, basic, and $0.76 per share, diluted, and for the twelve months of 2005 by $1.08 per share, basic, and $0.83 per share, diluted. The Company currently does not anticipate income tax benefits of this magnitude in the foreseeable future. Due to the recognition of the deferred tax assets in 2005, the Company currently expects, for financial statement purposes, an effective income tax rate of 38 percent in 2006.

 

Page 1


The following information was filed by Viropharma Inc (VPHM) on Tuesday, February 28, 2006 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Viropharma Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Viropharma Inc.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account